Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma, associated with significant morbidity and poor prognosis. Total Idiopathic Pulmonary Fibrosis (IPF) prevalent population in the 7MM is expected to rise to 284,823 in 2030. The therapies approved for mild-to-moderate Idiopathic Pulmonary Firbosis are: 1. Nintedanib 2. Pirfenidone